Your Good Partner in Biology Research

  1. 首页
  2. 试剂盒
  3. 酶联免疫试剂盒
  4. Human Delta-like protein 4(DLL4) ELISA kit

Human Delta-like protein 4(DLL4) ELISA kit

  • 中文名称：
    人δ样蛋白4(DLL4)酶联免疫试剂盒
  • 货号：
    CSB-EL006949HU
  • 规格：
    96T/48T
  • 价格：
    ￥3600/￥2500
  • 其他：

产品详情

  • 产品描述：

    This Human DLL4 ELISA Kit was designed for the quantitative measurement of Human DLL4 protein in serum, plasma, tissue homogenates. It is a Sandwich ELISA kit, its detection range is 23.5 pg/mL-1500 pg/mL and the sensitivity is 5.8 pg/mL.

  • 别名：
    AOS6 ELISA Kit; Delta 4 ELISA Kit; delta 4 precursor ELISA Kit; Delta ligand 4 ELISA Kit; delta ligand 4 precursor ELISA Kit; Delta like 4 ELISA Kit; Delta like 4 homolog ELISA Kit; Delta like 4 protein ELISA Kit; Delta like canonical Notch ligand 4 ELISA Kit; Delta like protein 4 ELISA Kit; Delta-like 4 (Drosophila) ELISA Kit; Delta-like protein 4 ELISA Kit; Delta4 ELISA Kit; DLL 4 ELISA Kit; Dll4 ELISA Kit; DLL4_HUMAN ELISA Kit; Drosophila Delta homolog 4 ELISA Kit; hdelta2 ELISA Kit; Homeobox protein DLL-4 ELISA Kit; MGC126344 ELISA Kit; Notch ligand delta 2 ELISA Kit; Notch ligand DLL4 ELISA Kit; Notch ligand DLL4 precursor ELISA Kit; XDLL-4 ELISA Kit
  • 缩写：
  • Uniprot No.：
  • 种属：
    Homo sapiens (Human)
  • 样本类型：
    serum, plasma, tissue homogenates
  • 检测范围：
    23.5 pg/mL-1500 pg/mL
  • 灵敏度：
    5.8 pg/mL
  • 反应时间：
    1-5h
  • 样本体积：
    50-100ul
  • 检测波长：
    450 nm
  • 研究领域：
    Developmental Biology
  • 测定原理：
    quantitative
  • 测定方法：
    Sandwich
  • 精密度：
    Intra-assay Precision (Precision within an assay): CV%<8%
    Three samples of known concentration were tested twenty times on one plate to assess.
    Inter-assay Precision (Precision between assays): CV%<10%
    Three samples of known concentration were tested in twenty assays to assess.
  • 线性度：
    To assess the linearity of the assay, samples were spiked with high concentrations of human DLL4 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
    SampleSerum(n=4)
    1:1Average %84
    Range %81-89
    1:2Average %94
    Range %90-98
    1:4Average %83
    Range %80-86
    1:8Average %87
    Range %83-90
  • 回收率：
    The recovery of human DLL4 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
    Sample TypeAverage % RecoveryRange
    Serum (n=5) 9591-99
    EDTA plasma (n=4)10096-104
  • 标准曲线：
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
    pg/mlOD1OD2AverageCorrected
    15002.261 2.298 2.280 2.098
    7501.575 1.595 1.585 1.403
    3750.989 0.975 0.982 0.800
    187.50.643 0.606 0.625 0.443
    940.434 0.429 0.432 0.250
    470.317 0.338 0.328 0.146
    23.50.267 0.278 0.273 0.091
    00.181 0.183 0.182
  • 数据处理：
  • 货期：
    3-5 working days

产品评价

靶点详情

  • 功能：
    Involved in the Notch signaling pathway as Notch ligand. Activates NOTCH1 and NOTCH4. Involved in angiogenesis; negatively regulates endothelial cell proliferation and migration and angiogenic sprouting. Essential for retinal progenitor proliferation. Required for suppressing rod fates in late retinal progenitors as well as for proper generation of other retinal cell types. During spinal cord neurogenesis, inhibits V2a interneuron fate.
  • 基因功能参考文献：
    1. These data indicate that DLL4 represents a new prognostic biomarker for nonsmall cell lung cancer , and DLL4 overexpression inhibits cell proliferation and metastasis in vitro. PMID: 30226615
    2. Study demonstrates that DLL4 is important in regulating the tumour growth of hepatitis B virus (HBV)-associated hepatocellular carcinoma as well as the neovascularization and suppression of HBV replication. PMID: 30228780
    3. this study revealed that DLL4 has pathophysiological roles on the progression of esophagus cancer cells, including migration, invasion and apoptosis, which indicated that DLL4 may be considered as a potent therapeutic target for the treatment of malignant esophageal cancer. PMID: 29749499
    4. The regulation of DLL4 by the LDB2 complex provides a novel mechanism of DLL4 transcriptional control that may be exploited to develop therapeutics for aberrant vascular remodeling. PMID: 28946938
    5. Data show that Delta-like 4 (DLL4) and Jagged1 (JAG1) displayed equal potency in stimulating Notch target genes in HMEC-1 dermal microvascular endothelial cells but had opposing effects on sprouting angiogenesis in vitro. PMID: 28445154
    6. epigenetic silencing and TP53 mutation have an effect on the expression of DLL4 in human cancer stem disorder PMID: 27542210
    7. the Notch signaling and atherosclerosis relevant markers in lesions from femoral arteries of symptomatic peripheral artery disease patients, were characterized. PMID: 28472949
    8. Data suggest that Numb acts as a Notch antagonist by controlling intracellular destination and stability of the Notch ligand Delta-like 4 (DLL4) through a post-endocytic sorting process; Numb negatively controls DLL4 plasma membrane recycling through well-documented recycling regulator protein AP1. PMID: 29042443
    9. Results show that DLL4 is involved in SYNJ2BP-induced hepatocellular carcinoma (HCC) development though activating its pathway. PMID: 27440153
    10. Positive Jagged1 and DLL4 expression is closely correlated with severe clinicopathological characteristics and poor prognosis in patients with gallbladder cancers. PMID: 27174628
    11. We show that GIT1, which also contains an ANK domain, inhibits the Notch1-Dll4 signaling pathway by competing with Notch1 ANK domain for binding to RBP-J in stalk cells PMID: 27926858
    12. Results provide evidence that DLL4 is associated with gastric cancer stem/progenitor cells (GCSPCs), and its expression impacts CSPC stemness characteristics associated with the Notch-1 pathway including self-renewal, differentiation, proliferation, and tumor formation. PMID: 27891816
    13. The s present novel structures of human ligands Jagged2 and Delta-like4 and human Notch2, together with functional assays, which suggest that ligand-mediated coupling of membrane recognition and Notch binding is likely to be critical in establishing the optimal context for Notch signalling. PMID: 28572448
    14. Overexpression of DLL4 could significantly attenuate the cytotoxic effects of docetaxel in MCF-7 cells by increasing Bcl-2 expression, while decreasing Bax expression, apoptosis rate and DNA damage PMID: 27334972
    15. In gastric epithelial cells co-cultured with Helicobacter pylori, the expression level of the ligand DLL4 was found to be significantly increased. PMID: 27073072
    16. Low DLL4 abundance in tumour cells may predict the benefit from adjuvant gemcitabine therapy after PDAC resection. PMID: 27755532
    17. Angiogenesis in Infantile haemangioma (IH) appears to be controlled by DLL4 within the endothelium in a VEGF-A isoform-dependent manner, and in perivascular cells in a VEGF-independent manner. The contribution of VEGF-A isoforms to disease progression also indicates that IH may be associated with altered splicing. PMID: 26957058
    18. Dll4 modulates liver inflammatory response by down-regulating chemokine expression PMID: 27171900
    19. Positive Jagged1 and DLL4 expression is closely correlated with severe clinicopathological characteristics and poor prognosis in patients with pancreatic ductal carcinoma. PMID: 27919854
    20. Data show that the IgA/delta-like protein 4 (Delta-4)/Notch receptor (Notch) axis is not observed in IgG-dendritic cells (DCs). PMID: 27117596
    21. Data suggest that the vascular DLL4-Notch4 signaling and VEGF signaling complementing each other plays an important role in the progression of tumor angiogenesis in primary glioblastoma. PMID: 26472724
    22. our data indicate that high DLL4 expression predicts pelvic lymph node metastasis and poor survival in cervical cancer. Therefore, DLL4 may be a potential clinical diagnostic marker for patients with early-stage cervical cancer. PMID: 26546434
    23. Cyclic AMP Response Element Binding Protein Mediates Pathological Retinal Neovascularization via Modulating DLL4-NOTCH1 Signaling PMID: 26870802
    24. DLL4 and JAG1 may have opposing effects on tumor angiogenesis in glioblastoma. PMID: 26546995
    25. Expression of D114 in the vessels of dermal microvasculature was shown to increase from 20 weeks of gestation to 20 years. PMID: 27487663
    26. Data indicate the role for altered forkhead box C2 (FoxC2)-Delta-like ligand 4 (Dll4)signaling in structural alterations of saphenous veins in patients with varicose veins. PMID: 26808710
    27. Antagonism of the DLL4-Notch signaling pathway might provide a potential therapeutic approach for breast cancer treatment by preventing angiogenesis. PMID: 26739060
    28. Activation of Dll4/Notch signaling led to increased expression of ephrin-B2 and subsequent inhibition of endothelial progenitor cells activity. PMID: 26212082
    29. DLL4 is a unique functional molecule of human circulating dendritic cells critical for directing Th1 and Th17 differentiation PMID: 26712946
    30. The expression of DLL4 was positively correlated with CD105-labeled MVD. PMID: 25986715
    31. The detection of Notch1 and Delta-like 4 expression in peripheral blood lymphocytes of renal transplant recipients can serve as a positive indicator for evaluating the diagnosis and treatment efficacy of the AR reaction. PMID: 26070613
    32. Among all the Notch ligands, Delta-like4 (Dll4) is specifically involved in angiogenesis. hD4R could suppress angiogenesis in vitro as manifested by network formation assay and sprouting assay. PMID: 25833803
    33. DLL4 and VEGFA expression was closely related to tumour diameter, clinical stage, histological grade and lymph node metastasis. PMID: 26111775
    34. DLL4/Notch1 and BMP9 interdependent signaling induces endothelial cell quiescence via P27KIP1/thrombospondin pathway. PMID: 26471266
    35. Overexpression of DLL4 is associated with thyroid tumor invasion and metastasis. PMID: 26241546
    36. Macrophage Dll4 promotes lesion development in vein grafts via macrophage activation and crosstalk between macrophages and smooth muscle cells. PMID: 26404485
    37. Heterozygous Loss-of-Function Mutations in DLL4 Cause Adams-Oliver Syndrome. PMID: 26299364
    38. IL-23 could promote migration of human ESCC cells by activating DLL4/Notch1 signaling pathway PMID: 26062426
    39. expression of VEGF and Dll4/Notch pathway molecules in ovarian cancer PMID: 24949865
    40. Dormant Dbf4 mRNA in immature GV oocytes is recruited by cytoplasmic polyadenylation during oocyte maturation and is dependent on MPF activity via its cytoplasmic polyadenylation element (CPE) PMID: 25348865
    41. High DLL4 expression is associated with T acute lymphoblastic leukemia. PMID: 25355291
    42. Inhibition of ADAM10/17 or knockdown of DLL4 reduced the proangiogenic effects of fibulin-3 in culture PMID: 25139440
    43. Dll4 expression is up-regulated in clear cell renal cell carcinoma patients, and predicts poor prognosis. PMID: 24966922
    44. Dengue virus up-regulates expression of notch ligands Dll1 and Dll4 through interferon-beta signalling pathway. PMID: 25041739
    45. Our data suggest that renal cell carcinoma progression is caused in part by activated DLL4/Notch signaling, interaction of endothelium and cells PMID: 24931473
    46. these results suggest that high expression of DLL4 is associated with axillary lymph node metastasis and a poor prognosis in breast cancer, suggesting its value as a diagnostic marker for breast cancer. PMID: 25260720
    47. These findings indicate a potential role for the Notch-1-Dll4 signaling pathway in foreign body-induced granulomatous reactions PMID: 24394305
    48. High expression of DLL4 is associated with metastasis in breast cancer. PMID: 24696220
    49. findings suggest that ADAM10/Dll4 signaling is a major signaling pathway in ECs driving inflammatory events involved in inflammation and immune cell recruitment PMID: 25130545
    50. Dll4-containing exosomes increase endothelial cell motility while suppressing their proliferation. PMID: 24504253

    显示更多

    收起更多

  • 相关疾病：
    Adams-Oliver syndrome 6 (AOS6)
  • 亚细胞定位：
    Cell membrane; Single-pass type I membrane protein.
  • 组织特异性：
    Expressed in vascular endothelium.
  • 数据库链接：

    HGNC: 2910

    OMIM: 605185

    KEGG: hsa:54567

    STRING: 9606.ENSP00000249749

    UniGene: Hs.511076